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Abstract A 50-year-old male patient with comorbid
human immunodeficiency virus developed a relapse of
bipolar disorder after a switch from oral aripiprazole
10 mg/day to intramuscular aripiprazole depot 200 mg
every 28 days plus oral aripiprazole 5 mg/day. The patient
was concomitantly taking lopinavir, saquinavir, ritonavir,
silybum marianum extract, and omeprazole. Only 1 week
after the switch, the patient developed mood swings, irri-
tability, depressive mood, and lack of drive. The oral
aripiprazole was increased again to stabilize the patient.
The measured trough drug concentration of aripiprazole
was low and may be correlated to the relapse. When oral
aripiprazole was increased back to 10 mg again, the
depressive symptoms subsided. The dose of the next depot
injection was increased to 300 mg and that of oral arip-
iprazole decreased back to 5 mg/day. Because trough drug
concentrations were still low after 28 days, the depot dose
was increased to 400 mg every 28 days, which is double
that recommended in the prescriber’s information. Two
months after the initial switch from oral to intramuscular
aripiprazole, the patient’s mood stabilized on aripiprazole
depot 400 mg every 28 days. More clinical data, especially
regarding the pharmacokinetic drug interactions of arip-
iprazole depot are needed to improve dosing recommen-
dations, and prevent relapses or adverse drug events.
Genetic polymorphisms may play an important role in the
clinical relevance of drug interactions concerning arip-
iprazole depot.
Key Points
The dosing recommendation of intramuscular
aripiprazole in the presence of cytochrome P450
inhibitors might need revision.
The pharmacokinetic drug interactions of
intramuscular aripiprazole might only be clinically
relevant in patients with the genetic polymorphism.
Introduction
Aripiprazole is a third-generation antipsychotic that is
indicated (in the USA) in the treatment of schizophrenia,
the acute treatment of manic and mixed episodes associated
with bipolar I disorder, in irritability associated with
autistic disorder, Tourette’s disorder, and as an adjunctive
treatment in major depression in adults. The recommended
dosage in bipolar disorder is 15 mg/day [1]. Drug inter-
actions are a common potential problem with numerous
medications used in psychiatry [2, 3]. According to the
aripiprazole package leaflet [4], the patients should inform
their physicians that they are also taking human immun-
odeficiency virus (HIV) medications. HIV medications are
inhibitors and inducers of cytochrome P450 (CYP)
enzymes and, if taken concomitantly with aripiprazole,
they can cause severe adverse drug events [5]. Ritonavir is
a known strong inhibitor of CYP3A4 and a moderate
inhibitor of CYP2D6 (Table 1), and, therefore, may
decrease the metabolism of aripiprazole, a CYP3A4 and
CYP2D6 substrate. Aripriprazole is primarily metabolized
by CYP3A4 and CYP2D6, about 40 % is metabolized to
the active metabolite dihydroaripiprazole [6].
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The US prescribing information [1] of aripiprazole
tablets recommends using only one quarter (in poor
metabolizers) or one half (in extensive or intermediate
metabolizers) of the regular dosage when administered
concomitantly with a strong CYP3A4 inhibitor. Itracona-
zole, a strong inhibitor of CYP3A4, increased the area
under the curve of oral aripiprazole by 50 % [7]. The US
prescribing information of aripiprazole depot [8] recom-
mends an aripiprazole dosage of 300 mg every 28 days
when it is administered concomitantly with a strong inhi-
bitor of CYP3A4 and of 200 mg when administered con-
comitantly with CYP3A4 and CYP2D6 inhibitors.
In this case study, we report details regarding a patient
with co-morbid bipolar disorder and HIV treated with
ritonavir, saquinavir, and lopinavir who experienced a
worsening of psychiatric symptoms when he was switched
from oral to depot aripiprazole.
Case Report
A 50-year-old Caucasian male patient (body mass index
26 kg/m2) with bipolar disorder (diagnosed 2007) and
comorbid HIV infection was receiving treatment with
intramuscular aripiprazole depot and HIV medications. He
had HIV for 20 years and had previously experienced
complications, including HIV-associated neurocognitive
disorder, myopathy (creatinine kinase elevation to 199
U/L), pneumocystis pneumoniae, herpes simplex infec-
tions, and zoster oticus infection. He also had a history of
chronic pain syndrome and arthritis, and was a smoker until
2011. He had been retired (owing to medical reasons) since
2006. His renal function was 99 mL/min chronic kidney
disease epidemiology collaboration equation in January
2015. He came to the psychiatric ambulatory care clinic in
January 2015 for the first time. He presented with lack of
concentration, lack of drive, mood swings, irritability, and
anxiety, and was diagnosed with generalized anxiety dis-
order. At the time of the switch to intramuscular aripipra-
zole depot, he was receiving the prescription medications
shown in Table 1. The patient had not been taking any
over-the-counter medications.
We collected several serum concentrations of aripipra-
zole as shown in Table 2 (trough concentrations, liquid
chromatography–mass spectrometry, blood collected in a
tube without gel for plasma separation). The therapeutic
reference range of aripiprazole according to the Arbeits-
gemeinschaft fu¨r Neuropsychopharmakologie und Phar-
makopsychiatrie (AGNP) consensus guideline [9] is
150–500 ng/mL. The ‘‘therapeutic reference ranges’’
define ranges of medication concentrations that specify a
lower limit below which a drug-induced therapeutic
response is relatively unlikely to occur and an upper limit
above which tolerability decreases or above which it is
relatively unlikely that therapeutic improvement may be
still enhanced. The therapeutic reference range is an ori-
enting population-based range that may not necessarily be
applicable to all patients [9].
On June 6, the patient started oral aripiprazole 5 mg
once daily. The dosage was increased to 10 mg/day, with
the patient reporting an improvement of all symptoms.
The first concentration on aripiprazole 10 mg was
94 ng/mL and hence within the expected dose-related
plasma concentration range of 86–128 ng/mL (based on
population data) according to the AGNP consensus
guideline [9].
Table 1 CYP and P-gp metabolism of drugs being received by the patient, based on information from the MediQ.ch (http://www.mediq.ch) drug
interaction database
Drug Dose, duration of
treatment
Substrate of Inhibits Induces
Lopinavir/
ritonavir








Saquinavir 1000 mg twice daily,
started 2005





179.85 mg once daily,
for years
CYP2C8 CYP2C9 (moderate)
Omeprazole 40 mg once daily, for
years
CYP2C19, P-gp CYP2C19, CYP3A4 (weak), P-gp
(moderate)
CYP1A2, CYP1A1
Aripiprazole 10 mg, started June 2015 CYP2D6, CYP3A4,
P-gp
P-gp (weak)
CYP cytochrome P450, P-gp P-glycoprotein
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On July 6, treatment was switched to aripiprazole depot
200 mg plus oral aripiprazole 5 mg/day. However, because
of mood swings and a worsening of depressive symptoms,
the dosage of oral aripiprazole was changed back to
10 mg/day on July 13. Owing to the unexpectedly low
aripiprazole concentration of 94 ng/mL while the patient
was receiving oral aripiprazole 10 mg/day (Table 2), and
the clinical worsening (depressive mood, mood swings,
irritability) shown after the injection of 200 mg plus oral
5 mg/day (concentration 143 ng/mL; Table 2), the dose for
the second and third injection of aripiprazole was increased
to 300 mg and the oral dosage was kept at 5 mg/day. At the
day of the third injection (August 3), the aripiprazole
concentration was 95 ng/mL (Table 2); oral aripiprazole
medication was stopped, and the dose of the depot was
increased to 400 mg for the fourth injection. The patient’s
mood stabilized with aripiprazole depot 400 mg every
28 days, and up to December 2015, no further pharma-
cotherapeutic intervention was needed; 400 mg is double
the recommended dose. The patient was monitored for
adverse drug reactions and relapse symptoms twice every
month. The concentration was 95 ng/mL on December 21.
The viral load of the patient was measured during that
time and was negative (HIV1-RNA negative, T-helper cells
613/lL, CD4/8 ratio 0.94), allowing us to verify the
patient’s compliance to the HIV medication.
Discussion
Dosing of aripiprazole depot accordingly to the prescribing
information [1] may result in low drug concentrations and
clinically worsening of symptoms with a risk for relapse, as
shown in this case report. The low drug concentrations
could be explained by a difference in pharmacokinetics:
intravenous and intramuscular administered drugs do not
undergo first-pass metabolism and have a bioavailability of
100 %, making drug interactions probably less clinically
relevant. The aripiprazole concentrations with an oral
dosage of 10 mg/day were as high as those with intra-
muscular depot 300 mg every 28 days plus oral 5 mg/day,
but still below the therapeutic range [9]. The low drug
concentrations after the first injections could also be
explained by the fact that the steady state after the injec-
tions is only reached after four to five injections. This
would mean that the patients are at a relapse risk at least for
the first month of the treatment with aripiprazole depot
when treated with the recommended dosage.
Few data have been published (PubMed search, key
words: aripiprazole ? drug interactions) with regard to
drug interactions with aripiprazole. One study found that
therapeutic doses of lithium and divalproex had no clini-
cally significant effects on the pharmacokinetics of oral
aripiprazole in patients with schizophrenia or schizoaffec-
tive disorder [10]. In a study of aripiprazole, fluvoxamine,
and paroxetine and the effects of genetic polymorphisms
[11], the influence of CYP3A4 inhibition on the pharma-
cokinetics of aripiprazole was not considered clinically
significant. However, interestingly, the researchers found a
difference between intermediate and extensive metaboliz-
ers with regard to aripiprazole clearance (clearance
decreased by 43 and 26.6 %, respectively), which could
support the theory that a drug–drug interaction with arip-
iprazole is not clinically significant until the patient has a
genetic polymorphism (intermediate or poor metabolizer).
This finding might be relevant for our case and support the
theory that our patient might be an extensive or ultra-rapid
metabolizer for CYP2D6 substrates, so that drug interac-
tions, even with strong inhibitors, such as HIV medica-
tions, did not cause clinically significant increases in drug
concentrations: the aripiprazole concentration with oral
aripiprazole 10 mg/day and also aripiprazole depot 300 mg
plus oral aripiprazole 5 mg were below the therapeutic
range, even though strong inhibitors of CYP3A4 and
CYP2D6 were present.
In another study conducted by Otsuka Pharma, co-ad-
ministration of itraconazole decreased the clearance of
aripiprazole in extensive metabolizers by 26.6 %, with an
even greater decrease of 47.3 % in intermediate metabo-
lizers, but did not affect the peak plasma concentrations of
aripiprazole. Overall, this drug interaction was not con-
sidered clinically significant [8].
Table 2 Time line of the aripiprazole doses and drug concentrations
Dose of aripiprazole
depot, mg (date)




5 (June 6–June 20)
10 (June 21–July 5) 94 (July 6)
200 (July 6) 5 (July 5–July 12) and 10 mg (July 13–August 2) 143 (August 3)
300 (August 3) 5 (August 3–31) 95 (August 31)
300 (August 31) 5 (August 31–September 28)
400 (September 28) 400 (October 26) 400 (November 23) 95 (December 21)
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This result, as well as those of our case report, does not
support the manufacturer’s dosing recommendation to
decrease the dose of aripiprazole by 50 % in presence of a
strong CYP inhibitor. The recommendation seems to be too
cautious and endanger the patient to relapse.
Conclusion
Without genetic testing or new dosing recommendations
for aripiprazole depot, therapeutic drug monitoring is a
reliable tool to assure drug therapy safety and efficacy of
aripiprazole. The drug interactions caused by inhibition of
CYP2D6 and CYP3A4 might not be clinically significant
in every patient, and may depend on the genetic poly-
morphism of the patient. There are no published studies
particularly on drug interactions of aripiprazole depot. The
interactions of the intramuscular formulation might also
not be clinically significant because of the different phar-
macokinetics (no first-pass metabolism, higher bioavail-
ability). More clinical data are needed to improve the
dosing recommendations for aripiprazole depot.
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